A Study of PRN1008 in Patients With Pemphigus
Public ClinicalTrials.gov record NCT03762265. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor Rilzabrutinib (PRN1008) in Moderate to Severe Pemphigus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a Phase 3 randomized, parallel-group, double-blind, placebo-controlled trial (blinded treatment \[BT\] period) followed by an open-label extension \[OLE\] period intended to evaluate the efficacy and safety of oral PRN1008 in moderate to severe pemphigus. After completing the open-label extension period, eligible participants might continue in a long term extension (LTE) Period of 48 weeks.
Study identification
- NCT ID
- NCT03762265
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 131 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 8, 2019 (Actual)
- Primary completion
- Jul 30, 2021 (Actual)
- Completion
- Dec 17, 2021 (Actual)
- Last update posted
- Aug 2, 2023
2019 – 2021
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Central Recruiting (Principia Biopharma) | Boca Raton | Florida | 33433 | — |
| Central Recruiting (Principia Biopharma) | Coral Gables | Florida | 33134 | — |
| Central Recruiting (Principia Biopharma) | Atlanta | Georgia | 30322 | — |
| Central Recruiting (Principia Biopharma) | Ann Arbor | Michigan | 48103 | — |
| Central Recruiting (Principia Biopharma) | Ann Arbor | Michigan | 48109 | — |
| Central Recruiting (Principia Biopharma) | Rochester | Minnesota | 55905 | — |
| Central Recruiting (Principia Biopharma) | Albuquerque | New Mexico | 87131 | — |
| Central Recruiting (Principia Biopharma) | New York | New York | 10016 | — |
| Central Recruiting (Principia Biopharma) | New York | New York | 10028 | — |
| Central Recruiting (Principia Biopharma) | Chapel Hill | North Carolina | 27599 | — |
| Central Recruiting (Principia Biopharma) | Durham | North Carolina | 27710 | — |
| Central Recruiting (Principia Biopharma) | Cleveland | Ohio | 44106 | — |
| Central Recruiting (Principia Biopharma) | Austin | Texas | 78705 | — |
| Central Recruiting (Principia Biopharma) | Murray | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 74 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03762265, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2023 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03762265 live on ClinicalTrials.gov.